Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Development of an APC and TP53-based duplex sequencing assay to positively predict colorectal cancer response to anti-EGFR therapy.

Cellular oncology (Dordrecht, Netherlands) - 13 Jan 2026

Yang Mingli, Schell Michael J, Salk Jesse J, Higgins Jake, Hipp Michael, Pflieger Lance, Pledger Warren Jack, Yeatman Timothy J

Abstract excerpt

PURPOSE: EGFR inhibitor (EGFRi) therapies have been FDA-approved for metastatic colorectal cancer (CRC). However, extended RAS/RAF testing required in the drug labels, identifies only non-responders, and only ~50% of selected patients respond to therapy, suggesting an unmet need to develop additional biomarkers. METHODS: We previously reported combined mutations in APC and TP53 as a potential positive biomarker...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenomatous Polyposis Coli Protein
Share to Cell Line, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Colorectal Neoplasms

Share to ErbB Receptors

Share to Protein Kinase Inhibitors

Share to Sequence Analysis, DNA

Share to Treatment Outcome

Share to Tumor Suppressor Protein p53

Source

Open in PubMed Open full text

Identifiers

PMID: 41528660
DOI: 10.1007/s13402-025-01140-y
PMCID: PMC12799675

Genes

APC
TP53
EGFR
BRAF
KRAS
NRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Development of an APC and TP53-based duplex sequencing assay to positively predict colorectal cancer response to anti-EGFR therapy.PMID 41528660Read ↗

Comprehensive assessment of actionable genomic alterations in primary colorectal carcinoma using targeted next-generation sequencing.Semantic proximity Read ↗

A multigene mutation classification of 468 colorectal cancers reveals a prognostic role for APC.Semantic proximity Read ↗

Optimization of RAS/BRAF Mutational Analysis Confirms Improvement in Patient Selection for Clinical Benefit to Anti-EGFR Treatment in Metastatic Colorectal Cancer.Semantic proximity Read ↗

Molecular Testing for the Treatment of Advanced Colorectal Cancer: An Overview.Semantic proximity Read ↗

Nanofluidic Digital PCR and Extended Genotyping of RAS and BRAF for Improved Selection of Metastatic Colorectal Cancer Patients for Anti-EGFR Therapies.Semantic proximity Read ↗

Mutation profiling of <i>KRAS</i> and <i>BRAF</i> in primary tumors and circulating tumor cells of colorectal cancer patients using PNA-LNA molecular switchSemantic proximity Read ↗

Targeted deep sequencing reveals APC mutations as predictors of overall survival in Chinese colorectal patients receiving adjuvant chemotherapy.Semantic proximity Read ↗

Clinical validation of the next-generation sequencing-based Extended RAS Panel assay using metastatic colorectal cancer patient samples from the phase 3 PRIME study.Semantic proximity Read ↗

Ion Torrent next-generation sequencing for routine identification of clinically relevant mutations in colorectal cancer patients.Semantic proximity Read ↗

APC and TP53 Mutations Predict Cetuximab Sensitivity across Consensus Molecular SubtypesSemantic proximity Read ↗

Development and Analytical Validation of a DNA Dual-Strand Approach for the US Food and Drug Administration-Approved Next-Generation Sequencing-Based Praxis Extended RAS Panel for Metastatic Colorectal Cancer Samples.Semantic proximity Read ↗

Changes in colorectal carcinoma genomes under anti-EGFR therapy identified by whole-genome plasma DNA sequencing.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.